Business
Korsana’s lead program uses a next-generation shuttling technology to improve delivery into the brain and lower the incidence of amyloid-related imaging abnormalities.
FEATURED STORIES
Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Lead Pharma has entered into a collaboration and license agreement with Roche, hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases.
The United States continues to headline an annual list of influential science researchers, but that lead is dipping as other global scientists gain recognition from their peers for the work they are conducting.
We have known since early on that diabetes is a complicating risk factor for developing severe illness from the SARS-CoV-2 virus that causes COVID-19. The hypothesis is now being floated by members of the medical community that COVID-19 may cause the disease to return – or potentially a unique version of it.
Immunotherapies are about to get safer, more effective, and even more accessible with the new biotech’s novel approach.
Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
The word “children” may come second in their name, but Seattle Children’s Hospital is proving they truly put children first.
George Chen left AstraZeneca after seven years to pursue his own line of oncology and immunology R&D.
Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global COVID-19 pandemic.
There are many examples of how biopharma is leveraging AI and forging partnerships with companies focused on AI for drug development and clinical trials. There have been a few recent AI-based partnerships as well.
Only about one in seven cancer patients today benefit from immunotherapy. OncoMyx aims to increase this number, using a new multi-armed, systemically administered and targeted oncolytic virus.